MSD to stop deliveries of hepatitis C drug Zepatira to Russia – Kommersant
[ad_1]
The American pharmaceutical manufacturer MSD has notified Roszdravnadzor that it will stop deliveries of Zepatira, a drug for the treatment of hepatitis C, to Russia. As Roszdravnadzor told Kommersant, this decision will not affect supplies scheduled for 2024.
Zepatier accounts for almost 20% of all public procurement of drugs against hepatitis C. More than 1 billion rubles are allocated annually for these purposes. The Ministry of Health of the Russian Federation has already warned federal medical institutions about the termination of the supply of several drugs, including Zepatir.
In March 2022, large pharmaceutical companies Pfizer, Lilly, AbbVie, Sanofi and MSD refused to conduct research in Russia. In July of the same year, MSD stopped deliveries of vaccines against chickenpox, rubella, measles and mumps to the Russian Federation.
Read more about the termination of the supply of zepatier – in the material “Kommersant” “Pharmaceutical market falls into hepatia”.
[ad_2]
Source link
